ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
rdf:type |
node1 |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
rdf:type |
rdfs:Resource |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
rdf:type |
owl:Thing |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
rdf:type |
prov:Person |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
rdf:type |
foaf:Person |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
rdf:type |
ripe:AuthorAuthor |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
owl:sameAs |
https://semopenalex.org/author/A5103550479 |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
http://www.w3.org/ns/org#memberOf |
ripekg:organization/RIPEO0471A30D61CB661ESection of Rheumatology |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
foaf:familyName |
Geborek |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
foaf:givenName |
Pierre |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |
foaf:name |
Pierre Geborek |
ripekg:work/10.1136%2Fannrheumdis-2014-205698Changes in the anticitrullinated peptide antibody response in relation to therapeutic outcome in early rheumatoid arthritis: results from the SWEFOT trial |
dcterms:creator |
ripekg:author/RIPEAUC71ACAB9842E61F1Pierre Geborek |